Abstract

Dapagliflozin (DPG) is a novel drug from class of sodium glucose co-transporter 2 (SGL-2) inhibitors which has been evolved as profound treatment option for the type-2diabetes mellitus (T2DM). Considering the severity of the disease the drug is of crucial significance for the therapy and associated research. As a pharmaceutical dosage form DPG has immense importance as an individual drug and with other antidiabetic drugs as combinations. The drugs existing in combination with DPG are Metformin (MET) and Saxagliptin (SXG). The existence of the Dapagliflozin in combinations further created more interest in reviewing its pharmaceutical, analytical and bio-analytical profile. Such estimations are always in need of precise pharmacological and physicochemical information; hence authors have presented it beforehand. Authors hereby wish to present an essential update pertaining to emergence of gliflozins and DPG. The article further presents a simultaneous and comparative assessment of the analytical investigations published in literature for pharmaceutical estimation to assist future analysis. The thorough literature searches revealed fifty three research papers in total till date. A comprehensive presentation of typical; hyphenated and unique methods used for analysis are outlined effectively. The percentile utilization of analytical approaches since appearance of first publication in 2010 is investigated to report trend in determination. The present review explores the pharmaceutical estimation of DPG to scientifically potentiate analytical research and therapeutic future of DPG as a novel SGL-2 Inhibitor antidiabetic.

摘要

Dapagliflozin (DPG) 是一种来自钠葡萄糖协同转运蛋白 2 (SGL-2) 抑制剂类的新型药物，已发展成为 2 型糖尿病 (T2DM) 的深度治疗选择。考虑到疾病的严重性，该药物对于治疗和相关研究具有至关重要的意义。作为一种药物剂型，DPG 作为一种单独的药物以及与其他抗糖尿病药物作为组合具有巨大的重要性。与 DPG 联合存在的药物是二甲双胍 (MET) 和沙格列汀 (SXG)。Dapagliflozin 组合的存在进一步激发了人们对其药学、分析和生物分析概况的更多兴趣。这种估计总是需要精确的药理学和物理化学信息；因此作者事先提出了它。作者在此希望提供有关格列净和 DPG 出现的重要更新。本文进一步对文献中发表的用于药物估计的分析调查进行了同步和比较评估，以协助未来的分析。迄今为止，彻底的文献检索共发现了 53 篇研究论文。典型的综合介绍；有效地概述了用于分析的连字符和独特的方法。调查了自 2010 年首次出版以来分析方法的百分位利用率，以报告测定趋势。本综述探讨了 DPG 的药物评估，以科学地增强 DPG 作为新型 SGL-2 抑制剂抗糖尿病药的分析研究和治疗前景。